Navigation Links
Most Off-Label Cancer Drug Use for Palliative Care
Date:10/27/2008

International review finds it's an accepted treatment in adults as well as children

MONDAY, Oct. 27 (HealthDay News) -- Between 1990 and 2002, off-label use of anticancer drugs in adults and children ranged between 6.7 percent and 33.2 percent, and most of that off-label use was for palliative care, say researchers who reviewed published studies from a number of countries.

In off-label use, a drug is used to treat conditions that aren't described on the official labeling created when a drug is approved by a regulatory agency such as the U.S. Food and Drug Administration.

Although off-label use of cancer drugs has been reported for most types of cancer, it's most common among patients with metastatic or advanced cancer who are receiving palliative care, noted study author Dr. Dominique Leveque, of the Hopital Hautepierre in Strasbourg, France.

While these patients aren't generally expected to experience clinical benefit, there are circumstances in which off-label anticancer drugs are accepted as the standard of care, such as the use of high-dose carboplatin in some childhood cancers.

But safety is a concern in off-label use, because there's likely little information about tolerance or side effects associated with this kind of use, Leveque said.

He concluded that more research into the extent of off-label use of anticancer drugs is needed and that accurate and unbiased data is urgently required to help doctors make treatment decisions.

The review was published in the November issue of The Lancet Oncology.

More information

The American Cancer Society has more about off-label drug use.



-- Robert Preidt



SOURCE: The Lancet Oncology, news release, Oct. 27, 2008


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Biopharmaceutical Company, Cephalon, To Pay $425 Million & Enter Plea to Resolve Allegations of Off-Label Marketing
2. Abortion drugs off-label use may have led to deaths
3. Off-Label Drug Use Needs Strong Oversight
4. Otsuka to Pay More Than $4 Million to Resolve Off-Label Marketing Allegations Involving Abilify
5. Largest ever analysis of DES data demonstrates safety, efficacy in on-and-off-label use
6. Statement from Eli Lilly and Company: Response to Todays New York Times Article, Lilly E-Mail Discussed Off-Label Drug Use
7. Off-Label Avastin Use for Wet Macular Degeneration
8. Study looks at off-label use of biliary stents
9. Get Screened Video Contest Throws a Spotlight on the Importance of Colorectal-Cancer Screening
10. MicroRNAs make for safer cancer treatments
11. Karmanos Cancer Center Most Preferred Hospital for Cancer Care in Southeast Michigan
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... ... March 24, 2017 , ... Empower Brokerage, located ... training and leads programs. , In February, 2017, Empower Brokerage introduced their new ... Partners is designed to teach how to maximize their sales efforts, as well ...
(Date:3/24/2017)... ... March 24, 2017 , ... “End Time GPS”: ... events will interrelate. “End Time GPS” is the creation of published author, Wesley ... while working on military munitions and space-vehicle projects. Now, at age ninety-one, he shares ...
(Date:3/24/2017)... ... ... Adventures of Joey, The Dog Who Barks at Puddles”: a boisterous story about a ... God intended. “The Adventures of Joey, The Dog Who Barks at Puddles” is the ... writing, especially about truth and human behavior. , Published by Christian Faith Publishing, Patti ...
(Date:3/23/2017)... Texas (PRWEB) , ... March 23, 2017 , ... The ... 3rd location in the greater Houston Area. The new location is located at 2255 ... Luke’s Hospital in Springwoods Village. This newest location will provide patients living in the ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... Center at 10 North Broadway Avenue, will be an educational and exciting program ... instruction in the management of chronic pain. , Oklahoma is in a healthcare ...
Breaking Medicine News(10 mins):
(Date:3/24/2017)... Mar. 24, 2017 Research and Markets ... the U.S.: Consumer Strategies" report to their offering. ... Pain ... approach and treat their physical pain, emphasizing consumer survey analysis, ... pain sufferers and adults who have selected illnesses/conditions strongly associated ...
(Date:3/24/2017)... , March 24, 2017 ShangPharma, ... high-quality and cost-effective drug development and discovery ... and biotechnology industry, announced today the intent ... ShangPharma will be consolidating the Contract Research ... under Shanghai ChemPartner. These entities include ChemPartner ...
(Date:3/24/2017)... , Mar. 24, 2017 Research and Markets ... Pipeline Analysis, 2016" report to their offering. ... The IPF pipeline is very strong with a ... Merck & Co., Inc., Biogen and Sanofi are involved in the development ... of which one is in Phase III stage, 15 are in Phase ...
Breaking Medicine Technology: